NCT04549922 - Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2021

Conditions

Covid19

Interventions

DRUG

ISIS 721744

1.2 mL of ISIS 721744 subcutaneous once after randomization

DRUG

Normal Saline

1.2 mL subcutaneous

Trial Locations (3)

Hospital Naval Marcílio Dias, Rio de Janeiro

BP-A Beneficiência Portuguesa de São Paulo, São Paulo

Hospital São Paulo - UNIFESP, São Paulo